665 results on '"Siccardi, Marco"'
Search Results
102. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
103. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient
104. Un approccio posturale ai Diametri Pelvici dell'Ostetricia: il Test di Pelvimetria Esterna Dinamica
105. Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide
106. Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach
107. CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz
108. Reports in Primal Osteopathy. Analisi e valutazione di due metodi di cambiamento posturale per la misurazione biodinamica dei diametri della losanga sacrale di Michaelis
109. Analysis of clinical drug-drug interaction data to predict uncharacterized interaction magnitudes between antiretroviral drugs and co-medications
110. How Osteopathy could help Obstetrics in diagnosis and therapy. Preliminary report about safety and efficacy of Osteopathy in an Obstetrics Department in Italy
111. La Pelvimetria Esterna Dinamica: dalla valutazione qualitativa alla misurazione strumentale. Test di Stork comparativo e test di Schober tramite il 'Kit Misuratore Osseo', Metrica, Milano (brevetto CE)
112. La forma dinamica della losanga sacrale di Michaelis: come si modifica la morfologia cambiando la postura
113. Il 'PELVIC INLET'. Considerazioni Anatomiche e Funzionali sullo Stretto Pelvico Superiore
114. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART
115. Improving maraviroc oral bioavailability by formation of solid drug nanoparticles
116. Towards a Maraviroc long-acting injectable nanoformulation
117. A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
118. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics
119. Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations
120. Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
121. Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro
122. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection
123. Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
124. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.
125. Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug‐Drug Interaction Magnitudes in the Elderly.
126. Ultrasonographic observation of a female fetus' sexual behavior in utero
127. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
128. Osteopatia per la Gravidanza. Risultati preliminari di uno studio analitico longitudinale controllato presso i punti nascita della ASL2 ligure
129. In vitro inhibition of P-glycoprotein by commonly used pharmaceutical excipients: implications for nanomedicine development
130. AMNIOTIC FLUID INDEX AND MATERNAL PLASMA VOLUME SHIFTS DURING 50 MINUTES OF MATERNAL IMMERSION IN DEEP THERMO-NEUTRAL WATER
131. Reports in Primal Osteopathy. La misurazione 'dinamica' dei diametri della losanga sacrale di Michaelis nel terzo trimestre di gravidanza: analisi e concordanza tra due metodi in tre posture
132. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
133. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
134. Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
135. Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach
136. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
137. The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation
138. Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
139. Development of Prodrug Approaches for Long‐Acting Nanoformulations of Emtricitabine‐Based Regimens
140. Improvements on the UTC(IT) timescale at INRIM
141. A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo
142. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
143. Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling
144. Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016)
145. Osteopatia per la Gravidanza: studio preliminare di outcome ostetrico presso gli ospedali della ASL2, provincia di Savona
146. Referee report. For: Nanoparticle-Based Antimicrobials: Surface Functionality is Critical [version 1; referees: 2 approved]
147. Chapter 2.2 - The Application of Nanotechnology to Drug Delivery in Medicine
148. Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
149. In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line
150. Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.